AMD

Metformin, a common diabetes medication, may be associated with less development of intermediate age-related macular degeneration (AMD).

MTII tracking in geographic atrophy reveals central macula preservation and predicts vision loss better than lesion area, shaping future trial endpoints.

Key clinical trial data and PDUFA dates in early 2026 focus on treatments for dry eye, AMD, and rare eye diseases.

The JADE clinical study enrolled more than 160 patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration (wAMD).

The letter noted the FDA is unable to approve the application for ONS-5010/LYTENAVA (bevacizumab-vikg) in its current form for the treatment of wet AMD, according to the company.

Strategies for treatment intervals, drug selection, and patient expectations.

A trio of retina specialists recently reviewed the clinical benefits of aflibercept 8 mg, including its extended dosing intervals, improved patient satisfaction, and enhanced treatment outcomes for various conditions.

This approach helps distinguish diseases associated with macular atrophy.

The company noted that this approval marks Celltrion's first Health Canada–approved biologic product in ophthalmology.

Additionally, the FDA approved a monthly dosing option for some patients who may benefit from resuming this dosing schedule across approved indications.

EyePoint Pharmaceuticals' DURAVYU trials for wet AMD receive positive DSMC review, highlighting safety and potential for improved patient outcomes.

CoTx-101 is intended for the treatment of retinal vascular diseases, such as wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).

This resubmission follows the complete response letter (CRL) Outlook received in August 2025.

New five-year data reveal SYFOVRE significantly delays geographic atrophy progression, enhancing understanding of age-related macular degeneration treatment.

Ophthalmologists weigh in on how the extended-duration therapy may reduce treatment burden for patients with wet age-related macular degeneration.

Harpal Sandhu, MD, FRCSC, discusses the preclinical performance of XPK-640 and how Optigo’s hyaluronic acid-anchoring platform may reshape dosing expectations in retinal disease.

The trial is evaluating 4D-150 in patients with wet age-related macular degeneration (wet AMD).

The trial will be evaluating AXPAXLI dosed every 6 months versus aflibercept (2 mg) dosed every 8 weeks in treatment-naïve wet AMD patients.

This acquisition will include Adverum’s lead candidate, Ixo-vec, a gene therapy treatment for wet AMD.

Emerging anti-VEGF agents offer enhanced durability and anatomic outcomes in retinal disease.

Regeneron faces another FDA setback for Eylea HD due to manufacturing issues, but plans for new facilities signal future production improvements.

AMD treatment may become unrecognizable as gene therapies evolve.